Per dose: Powd for inj Meningococcal group A oligosaccharide 10 mcg, soln for inj Meningococcal group C oligosaccharide 5 mcg, meningococcal group W135 oligosaccharide 5 mcg, meningococcal group Y oligosaccharide 5 mcg
Indications/Uses
Active immunization of adults & childn from 2 yr at risk of exposure to Neisseria meningitidis groups A, C, W135 & Y to prevent invasive disease.
View Menveo overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity to vaccine, diphtheria toxoid (CRM197) or life-threatening reaction after previous inj. Postpone vaccination in patients suffering from acute severe febrile illness.
Hypersensitivity. Not to be administered SC, intravascularly or intradermally. Not for protection against infections caused by any other serogroups of N meningitidis not present in vaccine. Individuals w/ familial complement deficiencies, functional or anatomical asplenia. Syncope; thrombocytopenia, bleeding disorders. Immunocompromised patients. Avoid injury from fainting. Concomitant use w/ anticoagulant therapy. May affect ability to drive & use machines. Pregnancy. Childn <2 yr. Elderly >65 yr.
J07AH08 - meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated ; Belongs to the class of meningococcal bacterial vaccines.
Sign Out
